Bliss GVS Pharma - appoints Rahul Adakmol as CEO effective July 15, 2026

Bliss GVS Pharma has announced the appointment of Rahul Adakmol as Chief Executive Officer, effective July 15, 2026. Adakmol brings extensive experience in the pharmaceutical sector, having previously led a six-year transformation at BSV, where he oversaw the development of a $100 million branded specialty business and contributed to a valuation of approximately USD 1.6 billion. His leadership was instrumental in expanding the company’s global footprint through strategic acquisitions and international partnerships.

Adakmol’s career highlights include scaling up a successful API business in Germany and fostering innovation in IVF and women’s health. His leadership style emphasizes team development and a collaborative approach, which has been credited with creating a strong organizational culture and driving significant growth.

In his new role, Adakmol will be responsible for steering the strategic direction of Bliss GVS Pharma, focusing on innovation, operational efficiency, and global expansion. The company has not disclosed further details about his specific objectives or the transition process. Investors and industry observers will be watching closely to see how Adakmol’s leadership impacts the company’s performance and market position in the coming months.